BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 24661665)

  • 1. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
    Chang JY; Li QQ; Xu QY; Allen PK; Rebueno N; Gomez DR; Balter P; Komaki R; Mehran R; Swisher SG; Roth JA
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1120-8. PubMed ID: 24661665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer.
    Chang JY; Balter PA; Dong L; Yang Q; Liao Z; Jeter M; Bucci MK; McAleer MF; Mehran RJ; Roth JA; Komaki R
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):967-71. PubMed ID: 18954709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
    Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
    Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.
    Li Q; Swanick CW; Allen PK; Gomez DR; Welsh JW; Liao Z; Balter PA; Chang JY
    Radiother Oncol; 2014 Aug; 112(2):256-61. PubMed ID: 25108807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
    Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
    J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer.
    Trovo M; Minatel E; Durofil E; Polesel J; Avanzo M; Baresic T; Bearz A; Del Conte A; Franchin G; Gobitti C; Rumeileh IA; Trovo MG
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1114-9. PubMed ID: 24661664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
    Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.
    Takeda A; Sanuki N; Eriguchi T; Kaneko T; Morita S; Handa H; Aoki Y; Oku Y; Kunieda E
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):257-63. PubMed ID: 23570699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.
    Liu H; Zhang X; Vinogradskiy YY; Swisher SG; Komaki R; Chang JY
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1017-23. PubMed ID: 22543216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer.
    Park HS; Harder EM; Mancini BR; Decker RH
    J Thorac Oncol; 2015 May; 10(5):832-837. PubMed ID: 25634007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy for central lung tumors.
    Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
    J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer.
    Register SP; Zhang X; Mohan R; Chang JY
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1015-22. PubMed ID: 20615629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.
    Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
    J Thorac Oncol; 2011 Dec; 6(12):2036-43. PubMed ID: 21892102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
    Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of 201 non-small cell lung cancer patients given stereotactic ablative radiation therapy shows local control dependence on dose calculation algorithm.
    Latifi K; Oliver J; Baker R; Dilling TJ; Stevens CW; Kim J; Yue B; Demarco M; Zhang GG; Moros EG; Feygelman V
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1108-13. PubMed ID: 24529716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.